I am thinking it may give some guidance towards the cancer targets for the basket trial. If another biomarker can be found, a more focused basket trial can take place.
As has been said a few times already, the FDA is proactive with helping drugs that treat unmet needs to market. They have approved CarT drugs with 79% adverse event rates, as the patient cohort have no other choice. This is the case with GBM.
Nothing is ever a sure thing until approval is done and dusted. But these results point to CHM having a drug with good prospects. As stockrock has already said, the next cohort results will be more indicitive of how the drug is going to work.
All we have to do is wait.
CHM Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)